<DOC>
	<DOCNO>NCT02462928</DOCNO>
	<brief_summary>This safety efficacy study abicipar pegol patient neovascular age-related macular degeneration .</brief_summary>
	<brief_title>A Safety Efficacy Study Abicipar Pegol Patients With Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diagnosis agerelated macular degeneration least 1 eye Best correct visual acuity 20/40 20/320 study eye Best correct visual acuity 20/200 good nonstudy eye History vitrectomy , macular surgery , glaucoma surgery study eye Cataract refractive surgery study eye within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>